Fiona Mccann

Fiona McCann PhD is an immunologist and has held the role of Scientific Director at 180 Life Sciences in UK since September 2018.

Fiona has obtained her PhD from studies at Pfizer and University of Kent, UK in 2000.

Since then she has carried out translational research at Imperial College London, and Kennedy Institute of Rheumatology (KIR), and has published several high impact studies with pharmaceutical companies (including Bayer Schering, Celgene, GSK) which unravel novel mechanisms of immune regulation, harnessing potential for therapeutic discovery.

From 2011-2018, she was group leader for therapeutic target discovery in autoimmune disease and fibrosis at University of Oxford, firstly working with NovoNordisk, and secondly with a multi-national consortium of academics and pharma at KIR/SGC Oxford (EU/IMI funded).

She holds a mini-MBA from SAID Business School, University of Oxford, a certificate in Entrepreneurs in Clinical Academia (ECA/FOCIS) from INSEAD business school, Fontainebleau, France and is currently studying towards a certificate in Project Management in Biotech at University of Washington and UCSD, due to complete June 2021.